PubRank

C W Vogel

Author PubWeight™ 42.48‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. Am J Pathol 1999 2.16
2 Cobra venom factor: improved method for purification and biochemical characterization. J Immunol Methods 1984 1.65
3 Differences in uptake of mycobacteria by human monocytes: a role for complement. Infect Immun 1988 1.32
4 Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. J Biol Chem 1984 1.26
5 MHC Class III products: an electron microscopic study of the C3 convertases of human complement. J Exp Med 1984 1.18
6 The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. J Biol Chem 1982 1.14
7 Cobra venom factor: structural homology with the third component of human complement. J Immunol 1984 1.10
8 Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients. J Clin Microbiol 1995 1.07
9 A molecular mechanism of complement resistance of human melanoma cells. J Immunol 1986 1.04
10 Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement. J Biol Chem 1982 0.94
11 Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J Immunol 1994 0.93
12 Effect of complement consumption by cobra venom factor on the course of primary infection with simian immunodeficiency virus in rhesus monkeys. AIDS Res Hum Retroviruses 1999 0.93
13 A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor. J Biol Chem 1988 0.93
14 Classical complement pathway activation on nucleated cells. Role of factor H in the control of deposited C3b. J Immunol 1995 0.93
15 C3-cleaving membrane proteinase. A new complement regulatory protein of human melanoma cells. J Immunol 1990 0.92
16 Immobilized doxorubicin increases the complement susceptibility of human melanoma cells by protecting complement component C3b against inactivation. Proc Natl Acad Sci U S A 1986 0.90
17 Molecular cloning and derived primary structure of cobra venom factor. Proc Natl Acad Sci U S A 1994 0.90
18 A new cAMP affinity matrix for the rapid purification of protein kinase regulatory subunits. FEBS Lett 1979 0.87
19 Primary structure of cobra complement component C3. J Immunol 1992 0.87
20 Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase. Proc Natl Acad Sci U S A 1981 0.87
21 Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Clin Immunol Immunopathol 1987 0.85
22 Immunoreactivity and function of oligosaccharides in cobra venom factor. J Immunol 1994 0.85
23 Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci U S A 1996 0.85
24 Serotype distribution and secretory acid proteinase activity of Candida albicans isolated from the oral mucosa of patients with denture stomatitis. Oral Microbiol Immunol 1999 0.84
25 The effects of metal ions and temperature on the interaction of cobra venom factor and human complement factor B. J Biol Chem 1986 0.84
26 Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen. Cancer Res 1999 0.83
27 A continuous flow immunoassay for rapid and sensitive detection of small molecules. J Immunol Methods 1990 0.83
28 Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65. Cancer Res 1993 0.83
29 Hemolytic assay for venom phospholipase A2. Anal Biochem 1981 0.81
30 The effect of complement depletion on immunologically mediated middle ear effusion and inflammation. Clin Immunol Immunopathol 1986 0.80
31 Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. Immunobiology 1997 0.79
32 N-linked oligosaccharides of cobra venom factor contain novel alpha(1-3)galactosylated Le(x) structures. Glycobiology 2001 0.79
33 A carbohydrate-directed heterobifunctional cross-linking reagent for the synthesis of immunoconjugates. Anal Biochem 1991 0.79
34 Delivery of radionuclides to pretargeted monoclonal antibodies using dihydrofolate reductase and methotrexate in an affinity system. Cancer Res 1993 0.79
35 Resistance of human melanoma cells against the cytotoxic and complement-enhancing activities of doxorubicin. Cancer Res 1987 0.78
36 Growth arrest of solid human neuroblastoma xenografts in nude rats by natural IgM from healthy humans. Nat Med 1996 0.78
37 Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic. Mol Immunol 1990 0.78
38 Structural studies on the cobra venom factor: isolation, purification, crystallization and preliminary crystallographic analysis. Acta Crystallogr D Biol Crystallogr 2001 0.78
39 Effect of covalent attachment of immunoglobulin fragments on liposomal integrity. Biochemistry 1986 0.77
40 In vivo studies with covalent conjugates of cobra venom factor and monoclonal antibodies to human tumors. Haematol Blood Transfus 1985 0.77
41 The oligosaccharide chains of cobra venom factor are required for complement activation. Mol Immunol 1989 0.77
42 Mechanisms of in vivo anti-neuroblastoma activity of human natural IgM. Eur J Cancer 1997 0.77
43 Structure of the major oligosaccharide of cobra venom factor. Mol Immunol 1992 0.76
44 Cobra venom factor and human C3 share carbohydrate antigenic determinants. J Immunol 1987 0.76
45 The cobra complement system: I. The alternative pathway of activation. Dev Comp Immunol 1985 0.76
46 Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation. Bioconjug Chem 1995 0.76
47 Molecular cloning and derived primary structure of cobra venom factor. Proc Natl Acad Sci U S A 1995 0.75
48 Doxorubicin enhances complement susceptibility of human melanoma cells by extracellular oxygen radical formation. J Biol Chem 1987 0.75
49 The cobra complement system: II. The membrane attack complex. Dev Comp Immunol 1985 0.75
50 Spectrofluorometric and spectrodensitometric determination of chloroquine in plasma and urine. Tropenmed Parasitol 1975 0.75
51 Initial characterization of the apoptosis-inducing receptor for natural human anti-neuroblastoma IgM. Med Pediatr Oncol 2001 0.75
52 [Natural human IgM-antibodies in neuroblastoma therapy: preliminary findings of a phase I/II clinical trial]. Klin Padiatr 1999 0.75
53 A homogeneous immunoassay for the mycotoxin T-2 utilizing liposomes, monoclonal antibodies, and complement. Anal Biochem 1987 0.75
54 Novel trifunctional carrier molecule for the fluorescent labeling of haptens. Anal Biochem 1991 0.75
55 Antibody conjugates with cobra venom factor. Synthesis and biochemical characterization. J Immunol Methods 1987 0.75
56 The membrane attack complex of complement and its precursor proteins lack phospholipase activity. Mol Immunol 1983 0.75
57 Naturally occurring humoral cytotoxicity against neuroblastoma (NB) cells in healthy persons and NB patients. Pediatr Hematol Oncol 1997 0.75
58 Expression of a 260 kDa neuroblastoma surface antigen, the target of cytotoxic natural human IgM: correlation to MYCN amplification and effects of retinoic acid. Eur J Cancer 1997 0.75